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Summary Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone
releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition
five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had
progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted
disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated.
There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian
cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further
evaluated.
Despite the high response rates achieved with either single
agent platinum chemotherapy or platinum based combina-
tion chemotherapy in women with advanced epithelial
ovarian cancer, long term survival in this disease remains
poor with the majority of patients ultimately relapsing and
dying of their disease (Wharton et al., 1984). Thus there is a
need to improve chemotherapy for both initial therapy and
for relapsed ovarian cancer. Furthermore there is the need to
identify novel therapies for patients with a low probability of
responding to conventional cytotoxic chemotherapy (Black-
ledge et al., 1989).
Several studies have demonstrated the presence of both sex
steroid hormone receptors and gonadotrophin releasing hor-
mone (GnRHs) receptors in epithelial ovarian tumour cells.
It has been demonstrated that 50% of epithelial ovarian
cancers are positive for oestrogen receptors, whilst 53% are
progesterone receptor positive and 88% are androgen recep-
tor positive (Rao et al., 1990). Furthermore some 80% of
epithelial ovarian cancers possess low affinity, high capacity
binding sites for gonadotrophin releasing hormone (Emons et
al., 1989). Langdon et al. (1990) have demonstrated that 17
oestradiol will stimulate the growth of oestrogen receptor
positive human ovarian carcinoma cell lines and that tamoxi-
fen will inhibit this oestrogen stimulated growth. The func-
tional in vivo importance of this range of receptor expression
is uncertain and the use of hormone manipulations, such as
tamoxifen, have yielded variable and generally poor clinical
responses (Slotman & Rao, 1988).
Goserelin (Zoladex) is a synthetic long acting lutenising
hormone releasing hormone (LHRH) agonist which has been
shown to cause tumour shrinkage in premenopausal women
with breast carcinoma (Williams et al., 1986) and to a lesser
extent in postmenopausal women (Harris et al., 1989). This
agent has been shown to suppress circulating levels of lutenis-
ing hormone, follicle stimulating hormone, testosterone,
androstenedione and oestradiol in postmenopausal women
receiving the drug by monthly depot subcutaneous (sc) injec-
tions (Dowsett et al., 1988). Whilst this may not be relevant
in oophorectomised women, it has been shown that women
with epithelial ovarian cancer have higher levels of oestradiol
than postmenopausal controls (Mahlck et al., 1988). It may
therefore be postulated that oestradiol could increase growth
of epithelial ovarian cancer cells by means of an autocrine
loop. Therefore goserelin might be expected to exert its anti-
proliferative effect in epithelial ovarian cancer either due to a
direct action on tumour cells via GnRH receptors, and/or
secondary to its ability to lower circulating oestrogen and
androgen levels by suppression of secretion by ovarian
tumour cells. In order to test this hypothesis we have con-
ducted a phase II study of goserelin in women with epithelial
ovarian cancer.
Patients and methods
Women with histologically proven epithelial ovarian cancer
who had relapsed following at least one trial of
chemotherapy or who were considered too ill to receive
chemotherapy for their disease were studied. There was no
upper age limit. The details of these patients are shown in
Table I. All patients had disease that was evaluable clinically
or by ultrasound or computerised tomography (CT). Only
symptomatic patients were treated. Twenty nine of the 30
had received prior chemotherapy. In all of these 29 patients
chemotherapy had contained a platinum agent (either cis-
platin or carboplatin) as part of their regimen. Eight patients
had received prior endocrine therapy consisting of either
tamoxifen or megesterol acetate, and three patients had
received prior radiotherapy. One patient aged 90 years was
treated with goserelin as first line therapy because of her age
and poor performance status. The median interval between
the start of first line chemotherapy, in the 29 patients, and
disease progression was 52 (range, 0-285) weeks.
Patients were treated with monthly goserelin (Zoladex, ICI,
Alderley Edge) 3.6 mg sc, after local infiltration of the site
with lignocaine. Treatment was continued until disease pro-
gression became apparent.
At each monthly treatment patients were evaluated for
toxicity and response status. Disease status was evaluated by
clinical examination and sequential ultrasound or CT scann-
ing where relevant. Standard WHO criteria were used to
assess response and progression (WHO, 1979). Survival was
defined as the period from diagnosis to death and response
duration as the interval from response to disease progression.
Results
Patients received a median of two cycles (range, 1-11) of
goserelin. There were no complete responders but two (6.7%)
patients achieved a partial remission lasting 40 and 105
weeks respectively. One patient with a poorly differentiated
serous cystadenocarcinoma with an enlarged supraclavicular
node and involved paraaortic nodes had progressed after
three courses of carboplatin and subsequently responded to
treatment with goserelin. The second responder who also had
a poorly differentiated serous cystadenocarcinoma had
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Table I Characteristics of 30 patients with epithelial ovarian cancer
treated with goserelin
Median age (years) 57.5 (38-90)
Median progression free interval (weeks)a 52 (0-285)
ECOG performance status 2 (0-2)
Histology
Serous 14
Mucinous 4
Clear cell 1
Endometroid 1
Mixed I
Undifferentiated 7
Borderline 2
Grade
Well differentiated 2
Moderately differentiated 4
Poorly differentiated 18
Undifferentiated 1
Borderline 2
Not classified 3
Prior therapy
Median number (range) of prior therapies 3 (0-6)
Chemotherapy 29
Chemotherapy (platinum based) 29
Hormone therapy 8
Radiotherapy 3
None 1
Sites of disease
Abdomen (including paraortic nodes) 22
Pelvis 17
Liver 6
Lung 2
Supraclavicular nodes 3
Skin 3
Ascites 10
Pleural effusions 3
aProgression free interval refers to the time following starting the
first chemotherapy regimen and the first relapse.
initially been treated with carboplatin and had disease
stabilisation for 7 months. On progression she had received a
second course of carboplatin, but had progressed after only
two cycles. After this she had progressed through treatment
with high dose tamoxifen and etoposide and subsequently
mitomycin C and 5 fluorouracil. Following this she under-
went debulking surgery which left her with a residual pelvic
mass. This responded to goserelin treatment. Five patients
had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks
respectively. Twenty three patients had progressive disease
and this included five early deaths. These five deaths occurred
before a second cycle ofgoserelin was given. Even if the early
deaths are counted as due to disease progression in the
analysis, then seven of the 30 patients (23%, 95% confidence
interval 10-42%) had absence of disease progression for 6
months or longer. There were no significant or unexpected
toxicities, other than the inconvenience for patients attending
hospital for subcutaneous injections, and the minor irritation
of the injection site seen in some patients. The median sur-
vival following commencement of goserelin treatment was 26
(range, 1-192) weeks. No subjective or objective toxicity was
witnessed.
Discussion
The fact that ovarian tumours possess sex hormone receptors
has meant that endocrine therapy for recurrent disease has
been regarded as an attractive alternative to conventional
cytotoxic chemotherapy. Most efforts at endocrine therapy in
epithelial ovarian cancer have concentrated on the use of
either progestagens or the antioestrogen tamoxifen. Several
progestagens have been used including 17-a-hydroxyproges-
terone, 17-a-hydroxy-19-norprogesterone-17-n-caproate, 6,
17-a-dimethyl-6-dehydroprogesterone, medroxyprogesterone
acetate, and megesterol acetate. Unfortunately response rates
with these agents have been disappointingly low ranging
from 10-15% (Slotman & Rao, 1988). The other most
widely used hormonal agent in the treatment of epithelial
ovarian cancer has been the antioestrogen tamoxifen which
has produced objective response rates from 0-10% (Slotman
& Rao, 1988). Despite the expression of oestrogen receptors
in a sizable proportion of human ovarian carcinomas, and a
positive relationship between tumour volume and plasma
oestradiol levels (Mahlck et al., 1988), the poor clinical
results with endocrine manipulations designed to perturb
oestrogen regulated tumour growth, suggest that this
mechanism of growth control is of only minor clinical impor-
tance.
We have used an LHRH agonist as it might be expected to
reduce tumour cell proliferation by both a direct action and
by reducing circulating levels of oestradiol, androstenedione
and testosterone. To date there have been only two studies
with LHRH agonists used in the treatment of advanced
epithelial ovarian cancer. Both of these studies have used
leuprolide. Kavanagh et al. (1989) achieved a 17% partial
response rate in 23 patients whom had been previously
treated with chemotherapy. Additionally a further two
patients had disease stabilisation. In a second study by
Bruckner and Motwani (1989) five patients were treated with
leuprolide and megesterol acetate and four of these patients
achieved an objective response.
Our phase II study of goserelin in advanced epithelial
ovarian cancer was the first to use goserelin. Our objective
response rate was only 6.7% (2/30) but most patients had
very advanced cancers and were heavily pre-treated. Further
more we included two patients with borderline malignancies
(pseudomyxoma peritoneii) whom are generally refractory to
most cytotoxic or endocrine therapies. Overall seven (23%)
patients had absence of disease progression for 6 months or
more. In advanced breast cancer absence of disease progres-
sion i.e. disease stabilisation for 5 months or more following
therapy confers the same survival benefit as partial response
to therapy (Howell et al., 1988). Thus the disease stabilisa-
tion seen in our patients may confer some survival advant-
age. LHRH agonists should be evaluated earlier in the
management of women with epithelial ovarian cancer, per-
haps at first relapse or in patients resistant to first line
conventional cytotoxic chemotherapy.
If our results are validated, then future studies could add-
ress the combination of goserelin with antiandrogens which
might provide better growth inhibition, targeting both
putative autocrine loop elements (LHRH receptors) and an
androgen mediated endocrine drive. Androgens may be of
greater importance in epithelial ovarian cancer than oestro-
gens since as many as 88% of these tumours were found to
express androgen receptors (Rao et al., 1990).
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